Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial

Simple item page
dc.contributor.authorGonzález San Segundo, C.
dc.contributor.authorLópez-Campos, Fernando
dc.contributor.authorGómez Iturriaga, Alfonso
dc.contributor.authorSantos, M.
dc.contributor.authorOcanto, Abrahams
dc.contributor.authorMontezuma, L.
dc.contributor.authorBoladeras-Inglada, A. M.
dc.contributor.authorGlaria, M.
dc.contributor.authorDuque Santana, Víctor
dc.contributor.authorCouñago Lorenzo, Felipe
dc.contributor.authorEt. al.
dc.date.accessioned2025-12-09T17:40:00Z
dc.date.available2025-12-09T17:40:00Z
dc.date.issued2025
dc.description.abstractURONCOR 06-24 (NCT05781217) is a prospective, multicenter, randomized, open-label, phase III trial evaluating the impact on distant metastasis-free survival (MFS) of short-term (6 months) versus long-term (24 months) androgen deprivation therapy (ADT) in combination with salvage radiotherapy in high- and intermediate-risk patients after biochemical recurrence (BCR). A total of 534 men will be randomized to receive either 6 or 24 months of ADT. Stratification is based on risk group (intermediate vs high) and nodal status (pN0 vs pNx).
dc.description.filiationUEM
dc.description.impactNo data 2024spa
dc.description.sponsorshipSin financiación
dc.identifier.citationGonzález San Segundo, C., López-Campos, F., Gómez Iturriaga, A., Santos, M., Ocanto, A., Montezuma, L., Boladeras-Inglada, A. M., Glaria, L., Guardado, S., Rodríguez, A., Henríquez, I., Olivera, J., Duque-Santana, V., Garre, J., Moreno, S., Valero, J., Conde, A. J., Doval, A., Sancho, G., … Couñago, F. (2025). Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. Actas Urológicas Españolas (English Edition), 49(7), 501823. https://doi.org/10.1016/j.acuroe.2025.501823
dc.identifier.doi10.1016/j.acuroe.2025.501823
dc.identifier.issn2173-5786
dc.identifier.urihttps://hdl.handle.net/11268/16587
dc.language.isoeng
dc.peerreviewedSi
dc.relation.publisherversionhttps://doi.org/10.1016/j.acuroe.2025.501823
dc.rights.accessRightsembargoed access
dc.subject.otherNeoplasias de la próstata
dc.subject.otherEnsayo clínico fase III
dc.subject.otherRecuperación mejorada después de la cirugía
dc.subject.sdgGoal 3: Ensure healthy lives and promote well-being for all at all ages
dc.subject.unescoInvestigación médica
dc.subject.unescoCáncer
dc.subject.unescoTratamiento médico
dc.titleDuration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial
dc.title.alternativeDuración de la deprivación androgénica con la radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía: datos iniciales de reclutamiento en el ensayo fase III URONCOR 06-24
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication116a6d00-95bc-49e5-a381-df10a08fde7a
relation.isAuthorOfPublication2e374c15-a9f7-4137-99a8-6be419e2c462
relation.isAuthorOfPublication.latestForDiscovery116a6d00-95bc-49e5-a381-df10a08fde7a

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Duration of androgen deprivation...2025.pdf
Size:
338.44 KB
Format:
Adobe Portable Document Format
Download

Collections

Área de Ciencias de la Salud